What is the most recent earnings date for DMP stock?
DERMAPHARM HOLDING SE (DMP.DE) last reported earnings on 3/17/2026.
FRA:DMP • DE000A2GS5D8
Past quarterly earnings results for DERMAPHARM HOLDING SE (DMP.DE), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in EUR): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | - | - | 294.902M | - | -5.36% | |||
| Q2 2025 | - | - | 272.146M | - | -2.74% | |||
| Q1 2025 | - | - | 302.396M | - | 1.24% | |||
| Q4 2024 | - | - | 290.67M | - | 8.14% | |||
| Q3 2024 | - | - | 311.602M | - | 9.54% | |||
| Q2 2024 | - | - | 279.802M | - | 6.40% | |||
| Q1 2024 | - | - | 298.691M | - | -6.40% | |||
| Q4 2023 | - | - | 268.798M | - | -7.48% | |||
| Q3 2023 | - | - | 284.466M | - | 8.10% | |||
| Q2 2023 | - | - | 262.969M | - | 9.81% | |||
| Q1 2023 | - | - | 319.118M | - | 37.76% | |||
| Q4 2022 | - | - | 290.517M | - | 6.53% | |||
| Q3 2022 | - | - | 263.139M | - | 8.54% | |||
| Q2 2022 | - | - | 239.479M | - | 11.11% | |||
| Q1 2022 | - | - | 231.641M | - | 9.16% | |||
| Q4 2021 | - | - | 272.716M | - | 25.88% | |||
| Q3 2021 | 1.15 | 0.99 | 16.19% | 173.81% | 242.446M | 248.76M | -2.54% | 21.85% |
| Q2 2021 | 0.74 | - | 236.36% | 215.538M | 216.65M | -0.51% | 16.05% | |
| Q1 2021 | 0.67 | 0.60 | 12.43% | - | 212.211M | 219.51M | -3.33% | 10.26% |
| Q4 2020 | 0.52 | - | - | 216.655M | 213.35M | 1.55% | - | |
| Q3 2020 | 0.42 | 0.43 | -3.29% | - | 198.978M | 205.03M | -2.95% | - |
| Q2 2020 | 0.22 | 0.38 | -42.68% | - | 185.727M | 189.22M | -1.85% | - |
| Q1 2020 | - | - | 192.469M | - | - |
Notes
DERMAPHARM HOLDING SE (DMP.DE) last reported earnings on 3/17/2026.
DERMAPHARM HOLDING SE (DMP.DE) missed EPS estimates and missed revenue estimates in the most recent quarter.